In one paragraphArticle in The Journal of experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
19 authors.
Valter Monteiro *Department of Immunobiology, Yale University School of Medicine, New Haven, CT, USA.ORCID 0000-0003-1785-6713 Joao C R Freitas *Instituto de Microbiologia, Universidade Federal do Rio de Janeiro , Rio de Janeiro, Brazil.ORCID 0000-0001-7247-0886 Jameson CrandellDepartment of Immunobiology, Yale University School of Medicine, New Haven, CT, USA.ORCID 0000-0003-2265-6548 Fernanda TanaDepartamento de Fisiologia e Biofísica, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.ORCID 0000-0002-4692-0836 Mallery I BrebanDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA.ORCID 0000-0002-8976-9988 Abigail PorzucekDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA.ORCID 0009-0002-5811-5727 Tauyne M RamiroLaboratório de Pesquisas em Virologia, Departamento de Doenças dermatológicas, Infecciosas e Parasitárias, Faculdade de Medicina de São José do Rio Preto, São José do Rio Preto, Brazil.ORCID 0009-0007-8656-2678 Ana B de OliveiraLaboratório de Pesquisas em Virologia, Departamento de Doenças dermatológicas, Infecciosas e Parasitárias, Faculdade de Medicina de São José do Rio Preto, São José do Rio Preto, Brazil.
Mauricio L NogueiraLaboratório de Pesquisas em Virologia, Departamento de Doenças dermatológicas, Infecciosas e Parasitárias, Faculdade de Medicina de São José do Rio Preto, São José do Rio Preto, Brazil.ORCID 0000-0003-1102-2419 David R MartinezDepartment of Immunobiology, Yale University School of Medicine, New Haven, CT, USA.ORCID 0000-0002-2940-8961 Nathan D GrubaughDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA.ORCID 0000-0003-2031-1933 Pedro R J AlmeidaDepartamento de Fisiologia e Biofísica, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.ORCID 0000-0003-0708-7797 Daniela WeiskopfCenter for Vaccine Innovation, La Jolla Institute for Immunology (LJI) , La Jolla, CA, USA.ORCID 0000-0003-2968-7371 Mauro M TeixeiraDepartamento de Fisiologia e Biofísica, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.ORCID 0000-0002-6944-3008 Funding
T Cell Responses Following DENV Natural Infections and Live-Attenuated Dengue Virus VaccinationP01AI106695 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI Eva Harris · 2015 to 2026
$34.1MQdenga Vaccine: Assessment of immunogenicity in a longitudinal cohort studyR21AI197057 · NIAID · YALE UNIVERSITY · PI Carolina Lucas · 2026 to 2026
$252kConselho Nacional de Desenvolvimento Científico e Tecnológico 444164/2024/3National Institute of Allergy and Infectious DiseasesNational Institute of Science and Technology in Dengue and Host-Pathogens Interactions 408527/2024-2NIAID NIH HHS R21 AI197057NIH HHS P01AI106695NIH HHS R21AI197057Stavros Niarchos FoundationYale Claude D. Pepper Older Americans Independence Center P30AG021342
6 · The paper itselfAbstract
Dengue causes over 390 million annual infections globally. Qdenga (TAK-003), the only widely available dengue vaccine, has an incompletely defined immunological profile. We performed longitudinal immunological profiling of 110 adults from a dengue-endemic region, including older adults (≥65 years), to assess the effects of immune imprinting and vaccine design on humoral and cellular immunity. Qdenga elicited B and T cell activation across groups but generated serostatus-dependent, serotype-skewed antibody responses. Only 8% of DENV-naïve individuals developed tetravalent neutralizing responses, whereas one-third responded to a single serotype, predominantly DENV-2, the vaccine backbone. DENV-exposed individuals mounted broader responses shaped by preexisting immunity, yet DENV-4 neutralization remained consistently poor. Neutralizing antibody titers plateaued after the first dose, with no increase following the second. These findings clarify why balanced tetravalent immunity is rarely achieved with Qdenga and demonstrate that both immune imprinting and vaccine backbone limit the breadth and magnitude of the responses. This has important implications for deployment, long-term protection in naive populations, and DENV-4-targeted boosters.
Indexed as
DengueDengue VaccinesDengue VirusAgedAntibodies, NeutralizingAntibodies, ViralB-LymphocytesFemaleHumansImmunity, CellularImmunity, HumoralMaleSerogroupT-LymphocytesAntibodies, NeutralizingAntibodies, ViralDengue Vaccines
What OpenQuestion holds
Textmetadata
Read underepoch 390